Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Plans’ Formulary Restrictions Will Get More Scrutiny In 2010 Bids – CMS

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency proposes that next year’s Part D bids report new drug utilization requirements in a clear and consistent way to make it easier to assess policy compliance.

You may also be interested in...

UnitedHealth Plans “Series” Of Part D Formulary Restrictions In 2009

National stand-alone Medicare drug plans co-sponsored by UnitedHealth and AARP will impose new formulary restrictions in major drug categories including cholesterol treatments, proton pump inhibitors and osteoporosis therapies in 2009 to help control costs

CMS Seeks Part D Prior Authorization Criteria Transparency In 2009

CMS is aiming to make Medicare Part D formulary prior authorization practices more clear and consistent by proposing new requirements for drug plans in its draft "call letter" to prospective plan sponsors for the 2009 benefit year

Medicare Part D Coverage For Obesity Drugs Urged By House Appropriations Panel

In the report accompanying FY 2023 HHS appropriations legislation, the House committee also addresses biosimilar uptake in Part D, Medicare dispensing fees for oral COVID-19 drugs and NIH grants for expanded access to investigational ALS drugs.


Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts